Solasta Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 16-11-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.95 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth -0.30%
(FY 2023)
- Total Assets -2.69%
(FY 2023)
About Solasta Laboratories
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹4.95 Cr.
Mehul Shah and Sunil Sukhathankar serve as directors at the Company.
- CIN/LLPIN
U74999MH2018PTC304867
- Company No.
304867
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Solasta Laboratories Private Limited offer?
Solasta Laboratories Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Aldehydes, Pharma Ingredients & Raw Materials, Pyridine Derivatives, Anti Inflammatory and Immunosuppressant API.
Who are the key members and board of directors at Solasta Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mehul Shah  | Director | 17-Mar-2023 | Current |
| Sunil Sukhathankar | Director | 17-Mar-2023 | Current |
Financial Performance of Solasta Laboratories.
Solasta Laboratories Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 0.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Solasta Laboratories?
In 2023, Solasta Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Precise Bio Pharma Private LimitedActive 19 years 8 monthsMehul Shah and Sunil Sukhathankar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Jun 2019 | ₹2.00 M | Open |
Others Creation Date: 28 Jun 2019 | ₹4.75 Cr | Open |
How Many Employees Work at Solasta Laboratories?
Unlock and access historical data on people associated with Solasta Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Solasta Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Solasta Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
